Aeglea BioTherapeutics
novel human enzyme in clinical development to treat due to beta deficiency | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
August 2020
Slide
17 of 28
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
June 2020
human enzyme being developed to beta | Aeglea BioTherapeutics
Related slides by other companies
23andMe
Investor Day
January 2022
using genetics to inform clinical development low head of therapeutics development | 23andMe
Ocuphire Pharma
Results
October 2022
topical eyedrops in clinical development for | Ocuphire Pharma
Vincera
SPAC
September 2020
clinical development plan | Vincera
Context Therapeutics
Investor Presentation
September 2022
clinical development strategy blocking cancer growth by combining and therapies stimulus estrogen progesterone | Context Therapeutics
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io